BioNTech Shares Fall 6% After BNT113 Trial Misses Key Endpoint

BioNTech shares fell about 6% in Tuesday trading after a Phase 2/3 trial of its BNT113 cancer therapy failed to meet one of its dual primary endpoints. Enna Lee reports on investing and digital-asset markets for TokenPost. Send corrections or tips to info@tokenpost.com.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.